These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
224 related articles for article (PubMed ID: 17085641)
1. Advances in targeting human epidermal growth factor receptor-2 signaling for cancer therapy. Meric-Bernstam F; Hung MC Clin Cancer Res; 2006 Nov; 12(21):6326-30. PubMed ID: 17085641 [TBL] [Abstract][Full Text] [Related]
2. Blockade of the HER family of receptors in the treatment of HER2-positive metastatic breast cancer. Sachdev JC; Jahanzeb M Clin Breast Cancer; 2012 Feb; 12(1):19-29. PubMed ID: 21903480 [TBL] [Abstract][Full Text] [Related]
3. Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer. Baselga J; Perez EA; Pienkowski T; Bell R Oncologist; 2006; 11 Suppl 1():4-12. PubMed ID: 16971734 [TBL] [Abstract][Full Text] [Related]
4. HER2/neu role in breast cancer: from a prognostic foe to a predictive friend. Ferretti G; Felici A; Papaldo P; Fabi A; Cognetti F Curr Opin Obstet Gynecol; 2007 Feb; 19(1):56-62. PubMed ID: 17218853 [TBL] [Abstract][Full Text] [Related]
5. Trastuzumab: targeted therapy for the management of HER-2/neu-overexpressing metastatic breast cancer. Emens LA Am J Ther; 2005; 12(3):243-53. PubMed ID: 15891269 [TBL] [Abstract][Full Text] [Related]
6. Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nahta R; Yu D; Hung MC; Hortobagyi GN; Esteva FJ Nat Clin Pract Oncol; 2006 May; 3(5):269-80. PubMed ID: 16683005 [TBL] [Abstract][Full Text] [Related]
7. Evolving strategies for overcoming resistance to HER2-directed therapy: targeting the PI3K/Akt/mTOR pathway. Nahta R; O'Regan RM Clin Breast Cancer; 2010 Nov; 10 Suppl 3():S72-8. PubMed ID: 21115425 [TBL] [Abstract][Full Text] [Related]
8. Progression and treatment of HER2-positive breast cancer. Davoli A; Hocevar BA; Brown TL Cancer Chemother Pharmacol; 2010 Mar; 65(4):611-23. PubMed ID: 20087739 [TBL] [Abstract][Full Text] [Related]
10. Adjuvant therapy with trastuzumab for HER-2/neu-positive breast cancer. Gonzalez-Angulo AM; Hortobágyi GN; Esteva FJ Oncologist; 2006 Sep; 11(8):857-67. PubMed ID: 16951389 [TBL] [Abstract][Full Text] [Related]
11. New insights into anti-HER-2 receptor monoclonal antibody research. Kumar R; Mandal M; Vadlamudi R Semin Oncol; 2000 Dec; 27(6 Suppl 11):84-91; discussion 92-100. PubMed ID: 11236033 [TBL] [Abstract][Full Text] [Related]
12. [Human recombinant anti-HER2 monoclonal antibody--a new targeted treatment in breast cancer]. Dank M Orv Hetil; 2001 Nov; 142(46):2563-8. PubMed ID: 11770175 [TBL] [Abstract][Full Text] [Related]
13. [Clinical aspects of trastuzumab treatment in breast cancer]. Grell P; Svoboda M; Fabián P; Petráková K; Vyzula R Klin Onkol; 2009; 22(1):3-10. PubMed ID: 19534433 [TBL] [Abstract][Full Text] [Related]
14. Beta1-integrin circumvents the antiproliferative effects of trastuzumab in human epidermal growth factor receptor-2-positive breast cancer. Lesniak D; Xu Y; Deschenes J; Lai R; Thoms J; Murray D; Gosh S; Mackey JR; Sabri S; Abdulkarim B Cancer Res; 2009 Nov; 69(22):8620-8. PubMed ID: 19887601 [TBL] [Abstract][Full Text] [Related]
15. Targeting fatty acid synthase-driven lipid rafts: a novel strategy to overcome trastuzumab resistance in breast cancer cells. Menendez JA; Vellon L; Lupu R Med Hypotheses; 2005; 64(5):997-1001. PubMed ID: 15780499 [TBL] [Abstract][Full Text] [Related]
16. Breast cancer: the upgraded role of HER-3 and HER-4. Karamouzis MV; Badra FA; Papavassiliou AG Int J Biochem Cell Biol; 2007; 39(5):851-6. PubMed ID: 17254832 [TBL] [Abstract][Full Text] [Related]
18. Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer. Spector NL; Blackwell KL J Clin Oncol; 2009 Dec; 27(34):5838-47. PubMed ID: 19884552 [TBL] [Abstract][Full Text] [Related]
19. HER2-positive early breast cancer and trastuzumab: a surgeon's perspective. Kulkarni S; Hicks DG Ann Surg Oncol; 2008 Jun; 15(6):1677-88. PubMed ID: 18398661 [TBL] [Abstract][Full Text] [Related]
20. HER2-targeted therapy in breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors. Nielsen DL; Andersson M; Kamby C Cancer Treat Rev; 2009 Apr; 35(2):121-36. PubMed ID: 19008049 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]